Cytospire Raises $83M Series A to Develop Pan‑gamma Delta T‑cell Engagers

Why It Matters

The funding backs a differentiated immunotherapy platform that could expand T‑cell engager efficacy into solid tumours, a market currently underserved and highly lucrative for pharma.

Key Takeaways

• Cytospire raised £61 million ($83 million) Series A funding.
• Focus on pan‑gamma‑delta T‑cell engagers for solid tumors.
• Lead candidate CYT X300 targets EGFR‑positive cancers.
• CEO Natalie Mount previously built companies acquired by Takeda.
• Investors include 4BIO Capital, Servier Ventures, and Abingworth.

Pulse Analysis

The class of bispecific T‑cell engagers has reshaped treatment for hematologic malignancies, yet their translation to solid tumors remains hampered by limited tumor penetration and cytokine‑release toxicity. Conventional formats tether CD3 on conventional αβ T cells, which often become excluded from the immunosuppressive tumor microenvironment. Gamma‑delta T cells, a minor yet innate‑like subset, naturally infiltrate tumors and can recognize stress‑induced ligands without major histocompatibility restriction. By engineering a pan‑gamma‑delta engager, Cytospire aims to exploit this biology, potentially delivering deeper tumor access while mitigating off‑target activation that fuels adverse events.

Cytospire secured a £61 million ($83 million) Series A round led by 4BIO Capital, with participation from Servier’s venture arm, Abingworth, and several strategic angels. The capital will fund pre‑clinical optimization of its flagship candidate, CYT X300, which is designed to bind EGFR on a range of solid tumours—including colorectal, head‑and‑neck, and non‑small‑cell lung cancer—while recruiting gamma‑delta T cells. Founder‑CEO Natalie Mount brings deep expertise, having steered Adaptate Biotherapeutics and GammaDelta Therapeutics to Takeda acquisitions, lending credibility to the platform and reassuring investors of a clear path to partnership or exit.

The market for next‑generation bispecifics is heating up, with large pharma allocating billions to acquire or license novel formats that can overcome solid‑tumor resistance. Cytospire’s pan‑gamma‑delta approach differentiates itself by targeting a cell type already present in the tumor niche, potentially reducing the high doses required for CD3‑based agents and improving safety margins. If CYT X300 demonstrates favorable pharmacokinetics and manageable cytokine profiles in early‑phase trials, the company could attract co‑development deals with established oncology players seeking to broaden their immunotherapy pipelines. Success would also validate gamma‑delta T cells as a versatile effector across multiple cancer indications.

Deal Summary

Cytospire, a London‑based biotech, announced a £61 million ($83 million) Series A round led by 4BIO Capital, with participation from Abingworth, Servier Pharmaceuticals’ venture arm and other investors. The funding will advance its pan‑gamma delta T‑cell engager platform, including preclinical development of CYT X300 for solid tumors. The round highlights growing investor interest in novel immunotherapy approaches.